Publication:
Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency

Loading...
Thumbnail Image
Full text at PDC
Publication Date
2015-05
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citations
Google Scholar
Research Projects
Organizational Units
Journal Issue
Abstract
The effect of the dinucleotide P1, P4-Di (adenosine-5') tetraphosphate (Ap4A) in improving adrenergic anti-glaucomatous delivery by modifying the tight junction proteins of the corneal epithelium was evaluated. Stratified human corneal epithelial cells (HCLE) were treated with Ap4A (100μM) for 5min and TJ protein levels and barrier function were analysed by western blotting and transepithelial electrical resistance (TEER), respectively. Western blot experiments showed a significantreduction at 2h (45% reduction of ZO-1 and 65% reduction of occludin protein levels) as compared to non-treated (control) cells. Two hours after Ap4A treatment, TEER values were significantly reduced (65% as compared to control levels (p<0.001)), indicating an increase in corneal barrier permeability. Topical application of Ap4A in New Zealand white rabbits two hours before the instillation of the hypotensor compounds (the α2-adrenergic receptor agonist, brimonidine and the β-adrenergic receptor antagonist, timolol), improved the delivery of these compounds to the anterior chamber as well as their hypotensive action on the intraocular pressure. The results obtained showed that, when Ap4A was topically applied two hours before the adrenergic compounds, the concentration of brimonidine in the aqueous humour increased from 64.3±5.3nM to 240.6±8.6nM and from 58.9±9.2nM to 183.7±6.8nM in the case of timolol, which also produces a more profound effect on IOP. Therefore, Ap4A treatment results in a better entrance of adrenergic anti-glaucomatous compounds within the eye and consequently improved therapeutic efficiency by increasing corneal epithelial barrier permeability
Description
Received 17 November 2014 / Received in revised form 28 January 2015 /Accepted in revised form 17 February 2015 / Available online 19 February 2015
Keywords
Citation
- Adamson, R.H., Liu, B., Fry, G.N., Rubin, L.L., Curry, F.E., 1998. Microvascular permeability and number of tight junctions are modulated by cAMP. Am. J. Physiol. 274, H1885-H1894. - Alm, A., 2014. Latanoprost in the treatment of glaucoma. Clin. Ophthalmol. 8, 1967-1985. - Balda, M.S., Gonzalez-Mariscal, L., Matter, K., Cereijido, M., Anderson, J.M., 1993. Assembly of the tight junction: the role of diacylglycerol. J. Cell. Biol. 123, 293-302. - Brown, R.C., Davis, T.P., 2002. Calcium modulation of adherens and tight junction function: a potential mechanism for blood-brain barrier disruption after stroke. Stroke 33, 1706-1711. - Brubaker, R.F., 2003. Targeting outflow facility in glaucoma management. Surv. Ophthalmol. 48 (Suppl. 1), S17-S20. - Burnstock, G., 2013. Introduction to purinergic signalling in the brain. Adv. Exp. Med. Biol. 986, 1-12. - Chen, Y., Lu, Q., Schneeberger, E.E., Goodenough, D.A., 2000. Restoration of tight junction structure and barrier function by down-regulation of the mitogenactivated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells. Mol. Biol. Cell 11, 849-862. - Denizot, F., Lang, R., 1986. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89, 271-277. - Frishman, W.H., Kowalski, M., Nagnur, S., Warshafsky, S., Sica, D., 2001. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. Heart Dis. 3, 386-397. - Gipson, I.K., Spurr-Michaud, S., Argueso, P., Tisdale, A., Ng, T.F., Russo, C.L., 2003. Mucin gene expression in immortalized human corneal-limbal and conjunctival epithelial cell lines. Invest Ophthalmol. Vis. Sci. 44, 2496-2506. - Gipson, I.K., Spurr-Michaud, S., Tisdale, A., Menon, B.B., 2014. Comparison of the transmembrane mucins MUC1 and MUC16 in epithelial barrier function. PLoS One 9 (6), e100393. - Guzman-Aranguez, A., Crooke, A., Peral, A., Hoyle, C.H., Pintor, J., 2007. Dinucleoside polyphosphates in the eye: from physiology to therapeutics. Prog. Retin Eye Res. 26, 674-687. - Guzman-Aranguez, A., Loma, P., Pintor, J., 2011. Focus on molecules: diadenosine tetraphosphate. Exp. Eye Res. 92, 96-97. - Harhaj, N.S., Antonetti, D.A., 2004. Regulation of tight junctions and loss of barrier function in pathophysiology. Int. J. Biochem. Cell. Biol. 36, 1206-1237. - Ikari, A., Takiguchi, A., Atomi, K., Sugatani, J., 2011. Epidermal growth factor increases clathrin-dependent endocytosis and degradation of claudin-2 protein in MDCK II cells. J. Cell. Physiol. 226, 2448-2456. - Ivanov, A.I., Samarin, S.N., Bachar, M., Parkos, C.A., Nusrat, A., 2009. Protein kinase C activation disrupts epithelial apical junctions via ROCK-II dependent stimulation of actomyosin contractility. BMC Cell. Biol. 10, 36. - Kass, M.A., Heuer, D.K., Higginbotham, E.J., Johnson, C.A., Keltner, J.L., Miller, J.P., Parrish 2nd, R.K., Wilson, M.R., Gordon, M.O., 2002. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120, 701-713 (Discussion 829-730). - Kiel, J.W., Hollingsworth, M., Rao, R., Chen, M., Reitsamer, H.A., 2011. Ciliary blood flow and aqueous humor production. Prog. Ret. Eye Res. 30, 1-17. - Klingler, C., Kniesel, U., Bamforth, S.D., Wolburg, H., Engelhardt, B., Risau, W., 2000. Disruption of epithelial tight junctions is prevented by cyclic nucleotidedependent protein kinase inhibitors. Histochem Cell. Biol. 113, 349-361. - Kompella, U.B., Kadam, R.S., Lee, V.H., 2010. Recent advances in ophthalmic drug delivery. Ther. Deliv. 1, 435-456. - Loftsson, T., Jansook, P., Stefansson, E., 2012. Topical drug delivery to the eye: dorzolamide. Acta Ophthalmol. 90, 603-608. - Loma, P., Guzman-Aranguez, A., Perez de Lara, M.J., Pintor, J., 2014. Diadenosine tetraphosphate induces tight junction disassembly increasing corneal epithelial permeability. Br. J. Pharmacol. - Mandel, I., Paperna, T., Volkowich, A., Merhav, M., Glass-Marmor, L., Miller, A., 2012. The ubiquitin-proteasome pathway regulates claudin 5 degradation. J. Cell. Biochem. 113, 2415-2423. - Mediero, A., Crooke, A., Guzman-Aranguez, A., Pintor, J., 2011. Phospholipase C/ Protein Kinase C pathway is essential for corneal re-epithelialization induced by Ap(4)A. Curr. Eye Res. 36, 1108-1115. - Mediero, A., Guzman-Aranguez, A., Crooke, A., Peral, A., Pintor, J., 2008. Corneal reepithelialization stimulated by diadenosine polyphosphates recruits RhoA/ROCK and ERK1/2 pathways. Invest Ophthalmol. Vis. Sci. 49, 4982-4992. - Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63. - Peral, A., Loma, P., Yerxa, B., Pintor, J., 2008. Topical application of nucleotides increase lysozyme levels in tears. Clin. Ophthalmol. 2, 261-267. - Pintor, J., Carracedo, G., Alonso, M.C., Bautista, A., Peral, A., 2002. Presence of diadenosine polyphosphates in human tears. Pflugers Arch. 443, 432-436. - Quigley, H.A., 2011. Glaucoma. Lancet 377, 1367-1377. - Rahman, M.Q., Ramaesh, K., Montgomery, D.M., 2010. Brimonidine for glaucoma. Expert Opin. Drug Saf. 9, 483-491. - Soto, D., Pintor, J., Peral, A., Gual, A., Gasull, X., 2005. Effects of dinucleoside polyphosphates on trabecular meshwork cells and aqueous humor outflow facility. J. Pharmacol. Exp. Ther. 314, 1042-1051. - Wang, Y., Zhang, J., Yi, X.J., Yu, F.S., 2004. Activation of ERK1/2 MAP kinase pathway induces tight junction disruption in human corneal epithelial cells. Exp. Eye Res. 78, 125-136. - Watanabe, K., Chiou, G.C., 1983. Action mechanism of timolol to lower the intraocular pressure in rabbits. Ophthalmic Res. 15, 160-167. - Weinreb, R.N., Khaw, P.T., 2004. Primary open-angle glaucoma. Lancet 363 (9422), 1711-1720.
Collections